.png)
Psychedelic Psychotherapy Annual Program
*Psychedelics-assisted therapy has not been approved by any regulatory agency. The safety and efficacy of Psychedelics-assisted therapy have not been established for the treatment of PTSD.
We are pleased to announce that at the beginning of the next academic year (Autumn 2024), the second one-year program for psychedelic therapy, in collaboration with Reichman University, the Hakomi Institute of Israel and MAPS Israel, will be launched.
Over the past 20 years, we have witnessed a renewal in the field of psychedelic research and therapy worldwide, as well as in Israel.
The use of MDMA and Psilocybin in therapy has been legalized in Australia and is currently undergoing advanced research stages in the United States in collaboration with the FDA.
Our expertise in psychedelic therapy is rooted in deep knowledge and experience in various fields related to the exploration of the mind and consciousness, including depth psychology (both dynamic and Jungian), integrative experiential psychotherapy, and inspiration from various spiritual traditions.
You are welcome to visit our program's website for more information and details.
*Psychedelics-assisted therapy has not been approved by any regulatory agency. The safety and efficacy of Psychedelics-assisted therapy have not been established for the treatment of PTSD.
MDMA Assisted Therapy Education Program
in collaboration with Lykos Therapeutics
*Midomafetamine (MDMA) capsules are not approved by any regulatory agency. The safety and efficacy of midomafetamine have not been established for the treatment of PTSD.
MDMA-Assisted Therapy Education Program
in collaboration with Lykos Therapeutics
MAPS Israel, in collaboration with Lykos Therapeutics, offers an educational program designed to educate attendees on the fundamental concepts of the inner-directed therapeutic approach used in the investigational midomafetamine (MDMA)-assisted therapy clinical trials.
With this approach, patients are supported to access their innate capacities for processing traumatic experiences in an empathetic and supportive environment.
This educational program provides a theoretical and educational framework suitable for therapeutic work with altered states of consciousness. The program has an online portion and an in-person educational week.
*Midomafetamine (MDMA) capsules are not approved by any regulatory agency. The
safety and efficacy of midomafetamine have not been established for the treatment of
PTSD
